Bringing medicine back to life?

Discover how Orfenix’ Vincent van der Wel reimagines existing drugs and navigates complex business landscapes with Orfenix, making treatments affordable and ensuring patients receive the care they need without high costs.

What We Do.

We turn great ideas into accessible medicines. To do that we work with academics to turn their ideas into reality and in a societally responsible manner. For us, this means building a sustainable business while ensuring patient access. Explore our portfolio to see how we realize that ambition.

Reformulating For Cystinosis

Repurposing For PXE

Repurposing For VWM

Academic Partners.

Insights.

Challenges in Clinical Trials for Orphan Drugs

Orphan drugs, which are developed to treat rare diseases, face unique challenges in clinical trials. While the incentives for developing orphan drugs, such as tax credits and market exclusivity, have encouraged pharmaceutical companies to invest in this area, the clinical trial process remains fraught with difficulties.

read more

Mastering EMA Briefing Documents: Essential Tips and Tricks

The European Medicines Agency (EMA) scientific advice procedure is designed to enhance communication between sponsors and regulators, streamlining the development of high-quality medicinal products. Preparing a clear and well-structured briefing document is key to obtaining meaningful feedback.

read more

Contact Orfenix.

For more information or to explore partnership opportunities, feel free to reach out to us anytime!

Follow us on LinkedIn

Meet the team